Skip to main content
. 2020 Nov 18;12(11):3413. doi: 10.3390/cancers12113413

Table 1.

Relative IC50 comparison among the bladder cancer cell lines used in the studies.

Cell Line Kras/Hras/Nras Status IC50 *
HT1376 Wild type >200 nM
T-24 Hras mutation ~13 nM
UMUC3 Kras mutation ~3 nM
RT112 Wild type >160 nM
253 J B-V Wild type >110 nM
TCCSUP (HTB-5) Wild type >160 nM
SNU-C2B (CRC) Kras mutation ~2.7 nM
HCT116 (CRC). Kras mutation ~0.51 nM

* IC50 is the 72 h FL118 treatment.